An interventional study of Blood flow restriction (Delfi Personalized Tourniquet System) and Standard rehabilitation in Meniscus Disorder, Meniscus, Torn Tibial and Meniscus Lesion, sponsored by University of California, San Francisco. Terminated at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Muscular Atrophy with a site in United States — 15 open to participants now, 26 under way, 2 of them phase 3. Muscular Atrophy · United States.
Among the 115 studies in Muscular Atrophy with a site in United States, this one is the 86th largest by enrollment of the 105 interventional ones that give a count, is one of 10 that started in 2020, is one of 57 with no phase, and was the 72nd registered.
413 studies on the registry are indexed under Muscular Atrophy; 77 are open to participants now.
Browse Muscular Atrophy studies →15 of the 115 studies in Muscular Atrophy with a site in United States are open now. Recruiting first, the newest first:
Sam Houston State University · Sites in United States
Ages 18–35 · Women only · Healthy volunteers
Brigham Young University · Sites in United States
Ages 18+ · Healthy volunteers
University of Utah · Sites in United States
Ages 60+ · Healthy volunteers
Michael C Willey · Sites in United States
Ages 65+
Tufts Medical Center · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Muscular Atrophy studies recruiting now, 25 (48%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 27 · Phase 3 13 · Phase 4 4
First in 1995; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 40 across 327 interventional studies indexed under Muscular Atrophy.
Median enrollment 40 across the 105 interventional studies, 61 across the 9 observational. Of the 81 that completed or were terminated, 41 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 115 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 371 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 203 (76%) have results posted.
University of California, San Francisco has 2 studies filed under Muscular Atrophy — fewer than ten, so there is no comparison to draw.
13 of the studies in Muscular Atrophy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06050668Michael C WilleyEssential Amino Acid Supplementation for Femoral Fragility Fractures | 2026-12 |
| NCT04809714University of Alabama at BirminghamThe Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture | 2026-12-13 |
| NCT07843095Sam Houston State UniversityProtein Supplementation During Luteal Phase to Stop Protein Degradation | 2026-12-17 |
| NCT06136221University of PennsylvaniaTesting LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease | 2026-12-30 |
| NCT03332238Hospital for Special Surgery, New YorkStromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 115 studies in Muscular Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate post-operative outcomes after meniscus surgery in participants undergoing blood flow restriction training as a rehabilitative adjunct compared to those with standard rehabilitation.
The investigators will conduct a double-blinded, single-institution, randomized controlled trial to compare patients undergoing arthroscopic meniscus repair with post-operative rehabilitation protocol as (1) a standard-of-care rehabilitative protocol with a non-occlusive blood pressure cuff (inflated to 20-30 mm Hg) applied to the operative extremity versus (2) blood flow restriction training with cuff occlusion applied to the operative extremity. Patients will be enrolled prospectively and pre-operatively at their initial clinic visit after meniscus injury.
Rehabilitative exercises would be advanced per the physical therapists' discretion with similar exercises for patients in both groups for direct comparison. These exercises are part of an already-established post-operative protocol that is in place, with the only difference being the addition of the blood flow restriction protocol in the intervention group. All patients would undergo their supervised post-operative rehabilitation at our institution.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The blood flow restriction arm will include the use of the pneumatic tourniquet applied to the operative lower extremity throughout post-operative rehabilitation sessions. The tourniquet pressure will be titrated to 80% of the measured extremity arterial limb occlusion pressure with the participant lying supine.
Device: Blood flow restriction (Delfi Personalized Tourniquet System) · Other: Standard rehabilitation
The standard rehabilitation arm will undergo the same rehabilitation protocol as the experimental arm. A tourniquet will still be applied, but will only be inflated to 20 mmHg, a pressure that will not occlude blood flow.
Other: Standard rehabilitation
The Delfi Personalized Tourniquet System will be utilized to apply the blood flow restriction protocol.
Also known as: Delfi Personalized Tourniquet System
Post-operative physical therapy as guided by a standardized protocol for patients undergoing meniscus repair.
Knee Extension Force at Week 1
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 1 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 2
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 2 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 3
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 3 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 4
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 4 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 5
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 5 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 6
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 6 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 7
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 7 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 8
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 8 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 9
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 9 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 10
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 10 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 11
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 11 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Knee Extension Force at Week 12
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
Time frame: Week 12 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 1
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 1 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 2
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 2 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 3
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 3 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 4
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 4 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 5
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 5 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 6
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 6 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 7
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 7 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 8
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 8 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 9
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 9 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 10
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 10 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 11
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 11 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Thigh Circumference at Week 12
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
Time frame: Week 12 (Evaluated weekly at physical therapy visits from 0-12 weeks)
International Knee Documentation Committee (IKDC) Score at Week 6
Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms
Time frame: 6 weeks (measured at 6 weeks, 3 months, and 6 months post-operatively)
International Knee Documentation Committee (IKDC) Score at Week 12
Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms
Time frame: 3 months (measured at 6 weeks, 3 months, and 6 months post-operatively)
International Knee Documentation Committee (IKDC) Score at Week 24
Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms
Time frame: 6 months (measured at 6 weeks, 3 months, and 6 months post-operatively)
Y-balance Testing at Week 12
Functional outcome measure (numerical score). The lower quarter Y-balance test evaluates dynamic stability and functional symmetry. The subject stands on a single leg and reaches in three directions (anterior, posteromedial, posterolateral) and a composite score is calculated as a percentage: (sum of reach distances in centimeters in each direction) / (3\*limb length) \* 100.
Time frame: 3 months (performed at 3 months and 6 months post-operatively)
Y-balance Testing at Week 24
Functional outcome measure (numerical score). The lower quarter Y-balance test evaluates dynamic stability and functional symmetry. The subject stands on a single leg and reaches in three directions (anterior, posteromedial, posterolateral) and a composite score is calculated as a percentage: (sum of reach distances in centimeters in each direction) / (3\*limb length) \* 100.
Time frame: 6 months (performed at 3 months and 6 months post-operatively)
3-hop Test at Week 12
Functional outcome measure (numerical score). The 3-hop test assesses dynamic stability and limb control. The subject hops three times consecutively forward in a same line and at the final landing, pauses in position while a measurement is made from the starting line to the toe at the end of the final hop in centimeters. The test is compared to the contralateral, uninjured limb, and scoring is reported as a percentage of the uninjured limb.
Time frame: 3 months (performed at 3 months and 6 months post-operatively)
3-hop Test at Week 24
Functional outcome measure (numerical score). The 3-hop test assesses dynamic stability and limb control. The subject hops three times consecutively forward in a same line and at the final landing, pauses in position while a measurement is made from the starting line to the toe at the end of the final hop in meters.
Time frame: 6 months (performed at 3 months and 6 months post-operatively)
Single Leg Squat Testing at Week 12
Functional outcome measure (numerical score). Single leg squat testing evaluates core stability and ability to perform functional movement safely. Subjects will be asked to perform a single leg squat and will be evaluated on 5 criteria, with one point for clinician-rated good performance in each (A) maintenance in balance, depth, speed (B) trunk posture (C) pelvic rotation \& tilt (D) Hip adduction or femoral internal rotation (E) knee joint apparent valgus. Min: 0 = poor balance and motor control; Max: 5 = good balance and motor control
Time frame: 3 months (performed at 3 months and 6 months post-operatively)
Single Leg Squat Testing at Week 24
Functional outcome measure (numerical score). Single leg squat testing evaluates core stability and ability to perform functional movement safely. Subjects will be asked to perform a single leg squat and will be evaluated on 5 criteria, with one point for clinician-rated good performance in each (A) maintenance in balance, depth, speed (B) trunk posture (C) pelvic rotation \& tilt (D) Hip adduction or femoral internal rotation (E) knee joint apparent valgus. Min: 0 = poor balance and motor control; Max: 5 = good balance and motor control
Time frame: 6 months (performed at 3 months and 6 months post-operatively)
| Milestone | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Started | 7 | 8 |
| Completed | 7 | 8 |
| Not completed | 0 | 0 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved Limb | 36.9 ± 30.3 | 21.0 ± 11.1 |
| Contralateral Limb | 87.1 ± 42.4 | 95.6 ± 54.7 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved Limb | 38.9 ± 29.8 | 33.7 ± 7.4 |
| Contralateral Limb | 93.0 ± 39.2 | 70.2 ± 34.8 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved Limb | 45.3 ± 34.3 | 29.6 ± 6.3 |
| Contralateral Limb | 110.3 ± 32.9 | 76.2 ± 51.2 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 48.0 ± 39.1 | 28.9 ± 4.0 |
| Contralateral limb | 112.1 ± 27.9 | 91.5 ± 34.0 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 49.7 ± 36.5 | 29.7 ± 7.3 |
| Contralateral limb | 117.8 ± 19.4 | 96.5 ± 37.5 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 62.3 ± 47.0 | 46.0 ± 18.8 |
| Contralateral limb | 118.8 ± 26.3 | 101.6 ± 33.2 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 64.9 ± 48.1 | 55.8 ± 16.6 |
| Contralateral limb | 121.5 ± 25.3 | 98.5 ± 35.8 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 77.7 ± 45.5 | 61.2 ± 31.4 |
| Contralateral limb | 122.1 ± 23.8 | 105.8 ± 51.0 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 82.3 ± 49.5 | 65.1 ± 21.0 |
| Contralateral limb | 119.6 ± 40.0 | 111.0 ± 40.2 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 83.1 ± 45.9 | 57.0 ± 10.4 |
| Contralateral limb | 118.4 ± 42.9 | 80.0 ± 31.2 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 81.2 ± 33.3 | 41.8 ± 3.5 |
| Contralateral limb | 112.6 ± 28.3 | 92.8 ± 39.1 |
Peak knee extension force (lbs) evaluated with a hand-held dynamometer
| lbs | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 96.1 ± 40.4 | 56 ± 13.2 |
| Contralateral limb | 126.3 ± 33.2 | 100.8 ± 21.8 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 42.9 ± 3.6 | 43.0 ± 5.8 |
| Contralateral limb | 43.4 ± 3.2 | 44.3 ± 6.4 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 43.5 ± 4.0 | 37.7 |
| Contralateral limb | 43.7 ± 3.7 | 39.6 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 43.3 ± 3.7 | 36.9 |
| Contralateral limb | 44.1 ± 3.6 | 39.6 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 43.2 ± 3.5 | 37 |
| Contralateral limb | 44.0 ± 3.3 | 37.6 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 43.1 ± 3.7 | 36.85 ± 0.07 |
| Contralateral limb | 44.3 ± 4.0 | 37.9 ± 0.4 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 44.9 ± 4.6 | 42.1 ± 5.2 |
| Contralateral limb | 44.9 ± 4.6 | 44.1 ± 6.1 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 43.2 ± 4.5 | 43.5 ± 5.1 |
| Contralateral limb | 44.4 ± 3.7 | 44.1 ± 6.4 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 44.8 ± 4.6 | 37.5 |
| Contralateral limb | 45.6 ± 3.5 | 37.6 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 44.0 ± 3.9 | 37.5 |
| Contralateral limb | 45.0 ± 3.2 | 38.0 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 43.8 ± 3.4 | 37.9 |
| Contralateral limb | 45.1 ± 3.2 | 38.0 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 42.3 ± 3.2 | 38.8 |
| Contralateral limb | 42.7 ± 2.5 | 38.0 |
Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh
| Centimeters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 43.3 ± 4.0 | 42.7 ± 3.5 |
| Contralateral limb | 43.9 ± 4.4 | 44.7 ± 6.1 |
Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms
| score on a scale | Blood Flow Restriction Group | Control Group |
|---|---|---|
| International Knee Documentation Committee (IKDC) Score at Week 6 | 24.7 ± 0.81 | 37.0 ± 3.8 |
Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms
| score on a scale | Blood Flow Restriction Group | Control Group |
|---|---|---|
| International Knee Documentation Committee (IKDC) Score at Week 12 | 41.4 ± 8.3 | 62.8 ± 6.9 |
Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms
| score on a scale | Blood Flow Restriction Group | Control Group |
|---|---|---|
| International Knee Documentation Committee (IKDC) Score at Week 24 | 75.3 ± 12.2 | 59.8 ± 8.3 |
Functional outcome measure (numerical score). The lower quarter Y-balance test evaluates dynamic stability and functional symmetry. The subject stands on a single leg and reaches in three directions (anterior, posteromedial, posterolateral) and a composite score is calculated as a percentage: (sum of reach distances in centimeters in each direction) / (3\*limb length) \* 100.
| Percentage of limb length | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 98.2 ± 6.6 | 95.4 |
| Contralateral limb | 109.1 ± 11.0 | 102.6 |
Functional outcome measure (numerical score). The lower quarter Y-balance test evaluates dynamic stability and functional symmetry. The subject stands on a single leg and reaches in three directions (anterior, posteromedial, posterolateral) and a composite score is calculated as a percentage: (sum of reach distances in centimeters in each direction) / (3\*limb length) \* 100.
| Percentage of limb length | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 92.5 | 96.8 ± 2.3 |
| Contralateral limb | 115.6 | 101.3 ± 3.7 |
Functional outcome measure (numerical score). The 3-hop test assesses dynamic stability and limb control. The subject hops three times consecutively forward in a same line and at the final landing, pauses in position while a measurement is made from the starting line to the toe at the end of the final hop in centimeters. The test is compared to the contralateral, uninjured limb, and scoring is reported as a percentage of the uninjured limb.
| Participants | Blood Flow Restriction Group | Control Group |
|---|---|---|
| 3-hop Test at Week 12 | 0 | 0 |
Functional outcome measure (numerical score). The 3-hop test assesses dynamic stability and limb control. The subject hops three times consecutively forward in a same line and at the final landing, pauses in position while a measurement is made from the starting line to the toe at the end of the final hop in meters.
| Meters | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Involved limb | 4.8 | 3.3 ± 1.7 |
| Contralateral limb | 5.7 | 3.4 ± 1.7 |
Functional outcome measure (numerical score). Single leg squat testing evaluates core stability and ability to perform functional movement safely. Subjects will be asked to perform a single leg squat and will be evaluated on 5 criteria, with one point for clinician-rated good performance in each (A) maintenance in balance, depth, speed (B) trunk posture (C) pelvic rotation \& tilt (D) Hip adduction or femoral internal rotation (E) knee joint apparent valgus. Min: 0 = poor balance and motor control; Max: 5 = good balance and motor control
| Participants | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Single Leg Squat Testing at Week 12 | 0 | 0 |
Functional outcome measure (numerical score). Single leg squat testing evaluates core stability and ability to perform functional movement safely. Subjects will be asked to perform a single leg squat and will be evaluated on 5 criteria, with one point for clinician-rated good performance in each (A) maintenance in balance, depth, speed (B) trunk posture (C) pelvic rotation \& tilt (D) Hip adduction or femoral internal rotation (E) knee joint apparent valgus. Min: 0 = poor balance and motor control; Max: 5 = good balance and motor control
| Participants | Blood Flow Restriction Group | Control Group |
|---|---|---|
| Single Leg Squat Testing at Week 24 | 0 | 0 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blood Flow Restriction Group | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Control Group | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Age, Continuous(years) | Blood Flow Restriction | Standard Rehabilitation | Total |
|---|---|---|---|
| Mean | 39.6 ± 7.7 | 35.4 ± 12.6 | 37.3 ± 10.4 |
| Sex: Female, Male(Participants) | Blood Flow Restriction | Standard Rehabilitation | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 5 | 6 | 11 |
| Race and Ethnicity Not Collected(Participants) | Blood Flow Restriction | Standard Rehabilitation | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Jun 2023, 31 months.
Results were first posted in Feb 2026, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →